NCT07274072 Hospital at Home Versus Inpatient Care: Costs and Effectiveness
| NCT ID | NCT07274072 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital at Home AG |
| Condition | Costs and Cost Analysis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-09-01 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background and Objectives Hospital at Home (HaH) delivers hospital-level treatment to acutely ill patients in their own homes, including daily medical and nursing visits, infusions, physiotherapy, and diagnostics. It bridges inpatient and outpatient care, working closely with hospitals, office-based physicians, home care services (Spitex), and therapy providers. There are two main pathways: Admission Avoidance: stable patients requiring hospitalization are admitted directly to HaH instead of an inpatient ward. Early Supported Discharge: patients treated in hospital are discharged earlier than usual and transferred to HaH. Evidence International studies show HaH to be safe and effective. Reviews report comparable mortality and rehospitalization, shorter hospital stays, and cost advantages. Admission avoidance is linked to trends toward lower mortality and costs. Research showed similar mortality but fewer rehospitalizations, longer treatment duration, and reduced risks of institutionalization, depression, and anxiety. HaH patients were older, with reduced daily living activities, yet care costs were on average USD 5,054 lower than inpatient care. In Switzerland, the mean hospital stay in 2019 was 8 days (acute somatic: 5.2; psychiatry: 33.5). Study Hypotheses HaH can be delivered at equal or lower cost than regular hospitalization. HaH care is safe, with few complications, and yields high patient satisfaction. Study Objective To demonstrate that hospital-equivalent home treatment of acutely ill patients is effective, appropriate, cost-efficient (according to Swiss WZW criteria), safe, and associated with high satisfaction and low complication rates compared with inpatient care. Endpoints Primary: Costs - HaH vs. inpatient care at Hirslanden Clinic, using REKOLE® cost accounting. Secondary: Mortality, therapy type, monitoring, diagnostics, rehospitalization, complications, satisfaction, patient-reported outcomes, length of stay, referrals to nursing homes, follow-up after discharge, ED visits, rehabilitation referrals, and home care type.
Eligibility Criteria
Inclusion Criteria: * Inpatients in the hospital or patients in Hospital at Home care * Age ≥ 18 years * Admission due to a typical Hospital at Home diagnosis (mild to moderate inflammatory and infectious diseases of the lungs, urinary tract, gastrointestinal tract, heart, and skin; exacerbated chronic obstructive pulmonary disease; exacerbation of chronic heart failure; wounds; bleeding/anemia; dehydration; deterioration of general condition in multimorbid patients; infection-related complications in oncological patients; psychiatric problems including delirium; metabolic or autoimmune diseases; orthopedic patients; pain exacerbations of any cause; palliative patients up to and including terminal situations) * Patients without severe cognitive impairment or dysfunction who are capable of providing informed consent and/or completing the questionnaire * Patients with sufficient proficiency in written and spoken German and/or English Exclusion Criteria: * Inpatient admission for other reasons * Refusal to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07274072 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Costs and Cost Analysis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07274072 currently recruiting?
Yes, NCT07274072 is actively recruiting participants. Contact the research team at kilian.braendle@hospitalathome.ch for enrollment information.
Where is the NCT07274072 trial being conducted?
This trial is being conducted at Zollikon, Switzerland.
Who is sponsoring the NCT07274072 clinical trial?
NCT07274072 is sponsored by Hospital at Home AG. The trial plans to enroll 200 participants.